Noida, India-based Jubilant Life Sciences‘ subsidiary Jubilant Pharma will negotiate a potential acquisition of a specialty business in the U.S., subject to due diligence, satisfactory agreements, and final approval of Jubilant Life Sciences.
BusinessLine reports on a company filing at the Bombay Stock Exchange that says, “the proposed acquisition is a niche, profitable specialty pharma business with a strategic fit and is expected to provide a competitive edge for Jubilant Life Sciences’ existing business, if it materializes.”
